Abstract
Ischemic heart disease including myocardial infarction develops on the basis of several risk-factors and comorbidities such as obesity, diabetes, hypertension, and hypercholesterolemia. Ischemic heart disease is the leading cause of mortality worldwide, therefore, identification of novel drug targets for cardioprotection is of great importance. Ischemic preconditioning, postconditioning, and remote conditioning trigger endogenous cardioprotective mechanisms that render the heart more resistant to lethal ischemic-reperfusion injury. However, major cardiovascular co-morbidities such as hyperlipidemia, diabetes, and their co-medications interfere with these cardioprotective mechanisms thereby limiting the efficacy of cardioprotective ischemic conditioning maneuvers. Ischemia reperfusion injury and cardioprotection by conditioning have been shown to affect global myocardial gene expression profile at the transcript level. Further understanding and the comprehensive analysis of the cardioprotective gene expression fingerprint in normal, protected, and in comorbid conditions may lead to identification of novel molecular targets for cardioprotection.
Keywords: Microarray, microRNA, miRNA, mRNA, postconditioning, preconditioning, proteomics, risk factors, sequencing, system biology, transcriptomics.
Current Drug Targets
Title:Functional Genomics of Cardioprotection by Ischemic Conditioning and the Influence of Comorbid Conditions: Implications in Target Identification
Volume: 16 Issue: 8
Author(s): Zoltan V. Varga, Zoltan Giricz, Peter Bencsik, Rosalinda Madonna, Mariann Gyongyosi, Rainer Schulz, Manuel Mayr, Thomas Thum, Laszlo G. Puskas and Peter Ferdinandy
Affiliation:
Keywords: Microarray, microRNA, miRNA, mRNA, postconditioning, preconditioning, proteomics, risk factors, sequencing, system biology, transcriptomics.
Abstract: Ischemic heart disease including myocardial infarction develops on the basis of several risk-factors and comorbidities such as obesity, diabetes, hypertension, and hypercholesterolemia. Ischemic heart disease is the leading cause of mortality worldwide, therefore, identification of novel drug targets for cardioprotection is of great importance. Ischemic preconditioning, postconditioning, and remote conditioning trigger endogenous cardioprotective mechanisms that render the heart more resistant to lethal ischemic-reperfusion injury. However, major cardiovascular co-morbidities such as hyperlipidemia, diabetes, and their co-medications interfere with these cardioprotective mechanisms thereby limiting the efficacy of cardioprotective ischemic conditioning maneuvers. Ischemia reperfusion injury and cardioprotection by conditioning have been shown to affect global myocardial gene expression profile at the transcript level. Further understanding and the comprehensive analysis of the cardioprotective gene expression fingerprint in normal, protected, and in comorbid conditions may lead to identification of novel molecular targets for cardioprotection.
Export Options
About this article
Cite this article as:
Varga V. Zoltan, Giricz Zoltan, Bencsik Peter, Madonna Rosalinda, Gyongyosi Mariann, Schulz Rainer, Mayr Manuel, Thum Thomas, Puskas G. Laszlo and Ferdinandy Peter, Functional Genomics of Cardioprotection by Ischemic Conditioning and the Influence of Comorbid Conditions: Implications in Target Identification, Current Drug Targets 2015; 16 (8) . https://dx.doi.org/10.2174/1389450116666150427154203
DOI https://dx.doi.org/10.2174/1389450116666150427154203 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthetic Cannabinoids as Drugs of Abuse
Current Drug Abuse Reviews Enhanced Antioxidant and Protective Activities on Retinal Ganglion Cells of Carotenoids-Overexpressing Transgenic Carrot
Current Drug Targets Inhibitors of the 5-Lipoxygenase Pathway in Atherosclerosis
Current Pharmaceutical Design Peroxisome Proliferator-Activated Receptors and the Control of Fatty Acid Oxidation in Cardiac Hypertrophy
Mini-Reviews in Medicinal Chemistry The Many Roles of Statins in Ischemic Stroke
Current Neuropharmacology Determining Effective Diabetic Care; A Multicentre - Longitudinal Interventional Study
Current Pharmaceutical Design Diagnostic and Therapeutic Nanoparticles in Cardiovascular Diseases
Current Pharmaceutical Design A Review on Biological Activities and Chemical Synthesis of Hydrazide Derivatives
Current Medicinal Chemistry ESVS Guidelines: Section A - Prevention in Patients with Carotid Stenosis
Current Vascular Pharmacology Bacterial Cell Wall Compounds as Promising Targets of Antimicrobial Agents II. Immunological and Clinical Aspects
Current Drug Targets Synthesis and Anti-tubercular Activity of 6-(<i>4</i>-Chloro/Methyl-phenyl)-4- Arylidene-4,5-dihydropyridazin-3(2<i>H</i>)-one Derivatives Against Mycobacterium tuberculosis
Letters in Drug Design & Discovery Applied Proteomics in Companion Animal Medicine
Current Proteomics Circulating Levels of Uric Acid and Risk for Metabolic Syndrome
Current Diabetes Reviews Is the Use of Cholesterol-Lowering Drugs for the Prevention of Cardiovascular Complications in Type 2 Diabetics Evidence-Based? A Systematic Review
Reviews on Recent Clinical Trials Association of Smoking and Alcohol Drinking with Dementia Risk Among Elderly Men in China
Current Alzheimer Research Cell Microencapsulation Implants into the Central Nervous System
Recent Patents on Nanomedicine Protein Kinases and Associated Pathways in Pluripotent State and Lineage Differentiation
Current Stem Cell Research & Therapy Roles of IL-6-gp130 Signaling in Vascular Inflammation
Current Cardiology Reviews Anti-Oxidant Gene Therapy by NFkB Decoy Oligodeoxynucleotide
Current Pharmaceutical Biotechnology Meet Our Editorial Board Member
Current Cardiology Reviews